文献速递毛发、甲与色素性疾病

额部纤维性脱发的头皮与血清分析揭示头皮免疫与纤维化失调而无全身受累

Scalp and serum profiling of frontal fibrosing alopecia reveals scalp immune and fibrosis dysregulation with no systemic involvement.
PubMed 文献 · J Am Acad Dermatol · 2021-05-24

本研究横断面分析33,118个头皮基因和350个血清蛋白,比较额部纤维性脱发(FFA)与正常及斑秃。FFA皮损中Th1、T细胞活化、纤维化、Treg及JAK/STAT相关基因差异表达,血清仅ADM蛋白差异表达,提示炎症局限于头皮。头皮生物标志物与疾病严重度及纤维化基因集相关。

要点

  • FFA表现为头皮局限性炎症,涉及Th1/JAK偏移及纤维化,无全身性受累。
  • 头皮IL-36RN/IL-25与疾病严重度相关,JAK/STAT与纤维化基因集相关。
  • JAK/STAT抑制可能为FFA提供疾病逆转潜力。

核心结论

  • FFA是一种局限于头皮的炎症性疾病,涉及Th1/JAK偏移、纤维化及Treg标志物升高,提示JAK/STAT抑制可能逆转疾病。

研究设计与样本

  • 横断面研究,对头皮33,118个基因进行RNA测序,对血清350个蛋白进行OLINK高通量蛋白组学分析,比较FFA与正常及斑秃。

主要发现

  • FFA皮损中差异表达基因包括Th1(IFNγ/CXCL9/CXCL10)、T细胞活化(CD2/CD3/CCL19/ICOS)、纤维化(CXCR3/FGF14/FGF22/VIM/FN1)、Treg(FOXP3/TGFB1/TGFB3)及JAK/STAT(JAK3/STAT1/STAT4)相关标志物(Fold changes [FCH]>1.5, FDR<.05 for all)。
  • FFA血清中仅ADM蛋白与正常有差异表达(FCH>1.3, FDR<.05)。
  • 头皮生物标志物(IL-36RN/IL-25)与FFA严重度显著相关,JAK/STAT与纤维化基因集显著相关(r>.6; P <.05)。

关键数值与推荐

  • 差异表达基因筛选标准:FCH>1.5且FDR<.05。
  • 血清差异蛋白筛选标准:FCH>1.3且FDR<.05。
  • 相关性分析显著性标准:P <.05,r>.6。

临床怎么用

  • FFA患者评估应关注头皮局部炎症和纤维化,无需常规系统筛查。
  • JAK/STAT抑制剂可能作为FFA的潜在治疗方向。
  • 头皮IL-36RN/IL-25或可作为疾病严重度的生物标志物。

局限性

  • 样本量小。
  • FFA患者以女性为主。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Frontal fibrosing alopecia (FFA) is a progressive, scarring alopecia of the frontotemporal scalp that poses a substantial burden on quality of life. Large-scale global profiling of FFA is lacking, preventing the development of effective therapeutics. OBJECTIVE: To characterize FFA compared to normal and alopecia areata using broad molecular profiling and to identify biomarkers linked to disease severity. METHODS: This cross-sectional study assessed 33,118 genes in scalp using RNA sequencing and 350 proteins in serum using OLINK high-throughput proteomics. Disease biomarkers were also correlated with clinical severity and a fibrosis gene set. RESULTS: Genes differentially expressed in lesional FFA included markers related to Th1 (IFNγ/CXCL9/CXCL10), T-cell activation (CD2/CD3/CCL19/ICOS), fibrosis (CXCR3/FGF14/FGF22/VIM/FN1), T-regulatory (FOXP3/TGFB1/TGFB3), and Janus kinase/JAK (JAK3/STAT1/STAT4) (Fold changes [FCH]>1.5, FDR<.05 for all). Only one protein, ADM, was differentially expressed in FFA serum compared to normal (FCH>1.3, FDR<.05). Significant correlations were found between scalp biomarkers (IL-36RN/IL-25) and FFA severity, as well as between JAK/STAT and fibrosis gene-sets (r>.6; P <.05). LIMITATIONS: This study was limited by a small sample size and predominantly female FFA patients. CONCLUSION: Our data characterize FFA as an inflammatory condition limited to scalp, involving Th1/JAK skewing, with associated fibrosis and elevated T-regulatory markers, suggesting the potential for disease reversibility with JAK/STAT inhibition.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Dubin C, Glickman JW, Del Duca E, et al. Scalp and serum profiling of frontal fibrosing alopecia reveals scalp immune and fibrosis dysregulation with no systemic involvement. J Am Acad Dermatol. 2021. PMID: 34044102. doi:10.1016/j.jaad.2021.05.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。